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ABSTRACT
Problems with the treatment of acute pain may
arise when a patient is opioid-tolerant, such as
those on chronic therapy with opioids or opiate
replacement therapy, those who misuse opioids, and those who are in recovery. While
some of the adverse effects of opioid
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medications are well known, it is also important
to recognize the roles of tolerance and hyperalgesia. Oliceridine can target and modulate a
novel l-receptor pathway. The G protein-biased
agonism of oliceridine allows for effective resensitization and desensitization of the muopioid receptor, which decreases the formation
of opioid tolerance in patients. Oliceridine has
been demonstrated to be an effective and relatively safe intravenous analgesic for the treatment of postoperative pain and is generally well
tolerated with a favorable side effect profile
when compared to morphine. As the prevalence
of pain increases, it is becoming increasingly
important to find safe and effective analgesics.

Keywords: Opioids; Oliceridine; Chronic pain;
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Key Summary Points
When a patient is opioid-tolerant, such as
those on chronic opioid therapy or opiate
replacement therapy, those who misuse
opioids, or those in recovery,
complications with acute pain treatment
may occur.
Oliceridine’s G protein-biased agonism
enables effective re-sensitization and
desensitization of the mu-opioid receptor,
preventing patients from developing
opioid tolerance. Oliceridine is an
effective and relatively safe intravenous
analgesic for the treatment of
postoperative pain.
It is generally well tolerated and has a less
severe side effect profile than morphine.
As pain becomes more prevalent, the
development of safe and effective
analgesics is critical.

INTRODUCTION
Pain is universal, and in its acute form serves as
a physiological response and protective mechanism to alert the body to current or foreseen
tissue damage [1, 2]. Nociceptors, a type of
peripheral neuron, play a crucial role in sensing
pain in the form of high temperatures, pressure,
and chemical irritants. Nociceptors also facilitate the transmission to higher orders of the
nervous system, including the brainstem and
cortex, for interpretation [3, 4]. While acute
pain often progressively resolves with tissue
healing, some acute pain may become chronic
pain through a process called ‘‘pain chronification’’ [5]. While the mechanism is not completely understood, chronic pain is becoming
increasingly prevalent. It is estimated that in
the United States alone, over 100 million adults
are affected at any given time by chronic pain,
with a healthcare cost of approximately
$560–635 billion per year [6]. With the growing

pervasiveness of chronic pain came a search for
effective pharmacological products to treat
pain. Opioids have been at the forefront of this
discussion.
In the 1990s, the American Pain Society
developed and published guidelines for acute
and chronic pain management in terms of
pharmacological approaches, with funding
from Purdue Pharma [7]. Purdue Pharma manufactured Percodan (oxycodone and aspirin)
and, later on, the longer-acting opioid, oxycodone [8]. With these guidelines, the 1990s
saw a massive rise in opioid prescriptions for
pain conditions. When oxycodone was
approved by the Food and Drug Administration
(FDA), it was marketed as suggesting that
addiction to the substance would be ‘‘rare,’’
based on a few small clinical trials. [9, 10]. In
the early 2000s, the American Pain Society’s
campaign continued to raise awareness among
physicians about assessing and managing pain
by publishing ‘‘Pain, the Fifth Vital Sign,’’ which
was regarded as having excellent credibility
[11]. This continued to encourage the liberal use
of opioids and initiated patient satisfaction
scores as a proxy for healthcare experiences.
Medicare then used these scores for disbursements, which put pressure on physicians to
continue prescribing the medication to ensure
patient satisfaction, which would boost their
compensation [12].
This information has additionally created a
search for effective pharmacological and nonpharmacological treatments of pain. While
opioids are a proven and effective method of
successful pain control, particularly in patients
with intractable cancer pain, the value of continued research on more effective strategies has
become clear in the field of medicine. Oliceridine, the subject of this paper, is an opioid
agonist indicated in adults for the management
of acute pain severe enough to require an
intravenous opioid analgesic.
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
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CURRENT TREATMENT
WITH OPIOIDS
Pharmacogenetics of Opioids
Modern medicine looks to opioid analgesics as
the gold standard treatment for nociceptive
pain, which commonly originates from cancer
therapy or surgical procedures. The endogenous
OPRM1 gene, located on chromosome 6, synthesizes l receptors which bind to opioid analgesics and allow for their effects to transpire.
Excretion of opioid analgesics is carried out via
polymorphic genes that code for phase I and
phase II hepatic enzymes. The metabolites can
also be excreted by the kidneys. Pharmacokinetic studies have shown that due to the polymorphic characteristics observed in hepatic
metabolism of drugs, individuals with different
polymorphisms have different exposure and/or
metabolism of opioid analgesics [13–16]. Some
studies also show that polymorphism affected
the pharmacodynamics of individuals. In turn,
the outcome of nociceptive pain care varied
from patient to patient. Currently, for the use of
tramadol and codeine, there are guidelines and
recommendations for physicians to appropriately individualize pain treatment for patients.
Of all opioids, these two are the only ones that
are restricted by these guidelines. However,
there are no such recommendations for other
opioids, so more research in this field is warranted [17].
Treatment of Acute Pain
Once the clinician has identified the underlying
cause of a patient’s pain, they formulate a disease-specific treatment plan. For mild to moderate pain, the suggested pharmacological
therapy is a nonsteroidal anti-inflammatory
drug (NSAID) or acetaminophen. Patient-specific risk factors guide physicians to prescribe one
or the other of these two drugs [18]. Undertreated mental illness is a risk factor for substance abuse [19]. A full review of attentiondeficit/hyperactivity disorder (ADHD), addiction history, depression, post-traumatic stress
disorder (PTSD), anxiety, sexual abuse, and a

family history of addiction should be evaluated
before prescribing an opioid. Problems with the
treatment of acute pain arise when the patient
is opioid-tolerant, such as those on chronic
therapy with opioids or opiate replacement
therapy, those who misuse opioids, and those
who are in recovery. General practitioners, as
well as anesthesiologists and surgeons, must
obtain a detailed history of these patients before
prescribing opioid analgesics. Importantly, the
specific opioids abused by the patient and the
last dose taken must be known to avoid the
onset of withdrawal. For this reason, multimodal anesthetics and analgesics are used in
combination when treating these patients to
achieve the most satisfactory treatment and
recovery [20].
It must be taken into consideration that not
every patient will be truthful about their opioid
use. To address this, clinicians have been educated about state prescription drug monitoring
programs and other screening tools that can be
used to identify current and potential opioid
abuse [21]. After surgery, most patients will
experience procedural pain and require some
anesthetic or analgesic for relief. However,
inappropriate treatment plans and prescription
of unnecessary opioids lead to the transformation of acute surgical pain into chronic surgical
pain or substance abuse disorders.
Treatment of Chronic Pain
A multicenter, phase IV trial was conducted to
determine the variability in response to opioid
treatment for chronic cancer pain. Five hundred
twenty patients who reported having moderate
to severe pain and required opioids to subdue
the pain were selected for the study. These
patients were placed in groups receiving oral
morphine, oxycodone, transdermal fentanyl or
buprenorphine for 28 days. Results showed that
the average pain intensity (API) decreased with
the use of all drugs. However, each group did
require adjustments to their treatment plan,
including increased daily dosage of opioids,
with fentanyl showing the highest increase of
121.2%. Also, each drug group required adjuvant analgesics to decrease the API [22].
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Misconceptions and Risks of Opioids
There is continuing controversy concerning the
efficacy and safety of opioids. For example,
hydromorphone (HM) is a potent opioid commonly used in the emergency department (ED).
HM is a short-acting opioid, a metabolite of
hydrocodone with poor bioavailability and a
very short half-life. HM displays typical opioid
pharmacodynamics by binding to the endogenous l receptors that elicit the analgesic and
euphoric effect [23]. Compared to morphine,
another commonly used opioid analgesic, HM
has similar efficacy and safety [24]. However,
with the exponentially increased use of HM in
the ED nationwide, there has also been an
increase in HM abuse and misuse. With this
evidence, it is recommended that physicians
seek out non-opioid analgesics to treat pain in
order to fight the growing incidence of opioid
abuse [23]. A systematic review was recently
conducted to determine the potential harms
and benefits that both physicians and patients
should be aware of when prescribing opioids for
lower back pain (LBP). From the studies included, it was determined that groups prescribed
oral opioids for subacute or chronic pain had
higher harm rates and lower pain improvement
than those who received non-opioid agents
[25].

OLICERIDINE
One of the significant downfalls of opioids
prescribed for pain management is the multitude of associated adverse effects. It was recently
discovered that a next-generation intravenous
opioid, oliceridine, can reduce or eliminate
many of the adverse effects of opioid treatment
while providing the analgesic benefits [26].
Oliceridine was fast-tracked in December 2015
and approved by the FDA in August 2020 for use
in moderate to severe pain that requires management via opioids [27]. Indications for using
oliceridine would be only if the first-line and
alternate therapies were not tolerated or did not
produce the desired outcome. Some contraindications of oliceridine include a hypersensitivity reaction to the opioid, life-

threatening respiratory depression, and paralytic ileus. As with most opioids, it is recommended that the patient be given the lowest
effective dose for the shortest duration to
maintain patient safety. Treatment with oliceridine should begin with a 1.5 mg dose. The
maximum dosage that should be administered
within a 24-hour period is 27 mg [26]. Two
randomized, double-blind trials, one that was
placebo-controlled and the other that was
morphine-controlled, aided in establishing the
safety and efficacy of oliceridine. Combined,
the studies included 790 adult patients who
suffered from moderate to severe pain after
orthopedic or abdominal surgery. Each trial had
some patients in the control, placebo, or morphine group, and the rest were divided into one
of three dosing groups of oliceridine. An initial
dose of 1.5 mg was given to each experimental
group; then the assigned groups either received
0.1 mg, 0.35 mg, or 0.5 mg of oliceridine. The
trial results concluded that the patients receiving 0.35 mg and 0.5 mg of oliceridine had significantly lower amounts of pain reported [28].
Oliceridine proved to be as effective and safe as
morphine when used as a treatment for nociceptive pain.
Mechanism of Action
Oliceridine, like many other opioids, relies on
the endogenous mu [l] receptors to bind to and
elicit an analgesic response to pain caused by
activated nociceptors. The l-opioid receptor
belongs to family A, the largest of three families,
and is classified as a seven-transmembrane
receptor. Much attention has been fixed on
specific G protein-biased agonism of the l-opioid receptor because it does not cause serious
adverse effects, unlike the other opioid medications [27]. This particular type of signaling
allows for G protein-coupled receptor (GPCR)
signaling without activating b-arrestin-mediated desensitization or signaling, which would
negatively regulate the GPCR activity and create
life-threatening adverse effects [29]. Oliceridine
is the first of its kind with the ability to target
and modulate this specific l-receptor pathway.
The G protein-biased agonism of oliceridine
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allows for effective re-sensitization and desensitization of the morphine opioid receptor
(MOR), which was shown to decrease the
development of opioid tolerance in patients
[29]. Since oliceridine is a full opioid agonist, it
should be mentioned that it has no maximum
analgesic effect, so the dosage must be highly
regulated to limit critical central nervous system
(CNS) depression [27].
An understanding of ligand binding and
allosteric modification on the receptor must be
achieved to create oliceridine. Molecular
dynamics simulations were done to observe the
ligand, TRV130, binding to the activated MOR.
The findings from this observation were compared to similar analysis of MOR bound to the
morphine ligand. These data should aid in furthering the design and development of
improved opioid analgesics [30].
Oliceridine Pharmacokinetics/
Pharmacodynamics
Since oliceridine is a G protein-biased ligand
that binds to MOR coupled to a b-arrestin
inhibitor, the pharmacokinetics and pharmacodynamics will be centered around this process. Oliceridine was seen to competitively bind
to the opioid receptor, but with a shorter duration compared to morphine [31]. From the
results of an in vitro study, oliceridine was
shown to have reputable distribution, with
plasma protein binding up to 77%. It has been
observed to be metabolized by the hepatic P450
enzymes CYP3A4 and CYP2D6 [26]. It should be
highlighted that the administration of oliceridine with CYP2D6 inhibitors or poor metabolizers of CYP2D6 will cause decreased clearance
of the opioid, which will increase the patient’s
exposure to the drug (and therefore the risk of
adverse effects). It should be discussed amongst
the healthcare providers whether or not the
patient should be taken off the CYP2D6 inhibitor or have the dosage of oliceridine lowered.
The dosage of oliceridine may need to be
increased if the patient being treated takes a
CYP3A4 inducer [32]. The pharmacodynamics
of oliceridine can affect multiple organ systems
within the body, such as the CNS,

gastrointestinal tract, and cardiovascular,
endocrine, and immune systems. The most
commonly noted effect of oliceridine is the
depression of respiration by its action on the
respiratory centers controlled by the medulla
oblongata, which can result in hypoxia if not
appropriately regulated. This novel opioid can
also cause decreased motility and contractility
of the intestines, delaying the digestion of food,
which can lead to constipation. Syncope and
orthostatic hypotension can result from the
vasodilation of peripheral blood vessels.

CLINICAL STUDIES: SAFETY
AND EFFICACY
Oliceridine/TRV130
A 2014 single-site study evaluated the safety,
tolerability, and pharmacological properties of
increasing TRV130 doses (0.15–7 mg IV) in
healthy subjects, including poor cytochrome
P450 2D6 (CYP2D6) metabolism on TRV130,
and the tolerability of short infusions. TRV130
showed good tolerance in all dosing groups,
with moderate adverse events occurring only in
the 7 mg dosing group. Plasma concentrations
were highest at the end of the 1-h infusion,
declining in multiple phases, indicating more
than one distribution compartment. CYP2D6
poor metabolizers had a TRV130 Cmax 1.35
times higher and clearance that was * 50%
lower when compared to their regular metabolizer counterparts. Infusions of 1.5 mg TRV130
for 1, 5, 15, and 30 min were well tolerated [33].
Another study done in 2014 showed that
TRV130 had higher peak analgesia that was
generally well tolerated with a reduced side
effect profile compared to morphine. A singlecenter, double-blind, randomized, placebocontrolled, crossover study evaluated l-opioid
receptor TRV130 agonism against placebo or
morphine IV for analgesia, safety, and tolerability in healthy male individuals. The subjects
received single doses of TRV130, morphine IV,
or placebo on every odd day for 10 days (days 1,
3, 5, 7, 9). TRV130 infusions were associated
with a decreased side effect profile up to the
4.5 mg dosage, where the side effects of TRV130
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Table 1 Clinical safety and efﬁcacy
Author
(year)

Groups studied and intervention

Results and ﬁndings

Conclusions

Viscusi
et al.
(2015)
[35]

Phase 2, randomized, double-blind, adaptivedesign study assessing the efﬁcacy and
tolerability of TRV130 in postoperative
bunionectomy patients. The ﬁrst phase
tested 1, 2, 3, or 4 mg IV TRV130 q4h
against placebo IV q4h and 4 mg
morphine IV q4h. The second phase
tested 0.5, 1, 2, or 3 mg q3h against
placebo IV q4h and 4 mg morphine IV
q4h

In the ﬁrst phase, 2 and 3 mg TRV130
showed better NRS TWA0-48 reductions
than placebo, similar to morphine. In the
second phase, TRV130 3 mg was more
statistically efﬁcacious than morphine
4 mg. No SAEs occurred in either phase
of the study for TRV130; though some
SEs were found (nausea, dizziness,
headache, and vomiting). TRV130 showed
a smaller effect on oxygen saturation than
morphine did

TRV130 showed statistically signiﬁcant pain
reduction compared to placebo and
morphine, with no SAEs and decreased
effect on oxygen saturation

Soergel
et al.
(2014)
[33, 34]

Single-site study evaluating the safety,
tolerability, and pharmacological
properties of increasing TRV130 doses
(0.15–7 mg IV) in healthy subjects, the
impact of poor cytochrome P450 2D6
(CYP2D6) metabolism on TRV130, and
the tolerability of short infusions

TRV130 was well tolerated, with moderate
AEs only in the 7 mg dosing group.
Plasma concentrations were highest at the
end of the 1-h infusion, declining in
multiple phases, indicating more than one
distribution compartment. CYP2D6 poor
metabolizers had a TRV130 Cmax 1.35
times higher and clearance that
was * 50% lower than normal
metabolizer counterparts. 1-, 5-, 15-, and
30-min 1.5 mg TRV130 infusions were
well tolerated

TRV130 was well tolerated, plasma
concentrations, and relatively low SE
proﬁle. CYP2D6 poor metabolizers had
signiﬁcantly altered pharmacokinetics and
indicate multiple distribution
compartments

Soergel
et al.
(2014)
[33, 34]

Single-center, double-blind, randomized,
placebo-controlled, crossover study that
evaluated l-opioid receptor TRV130
agonism against placebo or morphine IV
for analgesia, safety, and tolerability in
healthy male individuals. The subjects
received single doses of TRV130,
morphine IV, or placebo on odd days for
10 days

TRV130 infusions were associated with
decreased SE proﬁle up to 4.5 mg, where
the SEs of TRV130 were similar to those
associated with morphine IV; while
producing an equivalent analgesic effect.
TRV130 induced a temporary decrease in
respiratory drive that was markedly
decreased from the morphine-induced
respiratory drive that persisted through
4 h post-infusion

TRV130 showed higher peak analgesia
compared to morphine, along with
reduced SE proﬁle ,and was generally well
tolerated

Singla
et al.
(2019)
[36]

A phase 3, double-blind, randomized
placebo- and active-controlled study
evaluating the safety and efﬁcacy of
oliceridine in treating abdominoplastyrelated pain. The patients in the study
received a loading dose of oliceridine
1.5 mg, morphine 4 mg, or placebo IV,
which was then followed by demand doses
of 0.1, 0.35, and 0.5 mg either self- or
clinician-administered

All treatment groups except for the placebo
group showed a markedly decreased need
for rescue doses during the treatment. The
placebo group showed the highest
occurrence of rescue pain medication use.
Oliceridine-related SAEs were limited to
syncope and lethargy during the study,
while the other observed SAEs during
treatment were thought to be related to
other factors. GI AEs showed a
proportional dose-related relationship
with oliceridine use up to the 0.5 mg
oliceridine dose, where the incidence of GI
AEs was similar to the morphine group

Oliceridine was shown to be an effective and
relatively safe IV analgesic for the
treatment of postoperative pain related to
abdominoplasty

AE adverse event, GI gastrointestinal, NRS numeric rating scale, SAE serious adverse event, SE side effect
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were similar to those associated with morphine
IV; while producing an equivalent analgesic
effect. TRV130 induced a temporary decrease in
respiratory drive markedly shorter from the
morphine-induced decreased respiratory drive
that persisted through 4-h post-infusion [34].
In 2015, TRV130 showed statistically significant pain reduction compared to placebo and
morphine in the treatment of postoperative
bunionectomy pain. The phase 2, randomized,
double-blind, adaptive-design study assessed
the efficacy and tolerability of TRV130 in postoperative bunionectomy patients. The first
phase tested 1 mg, 2 mg, 3 mg, or 4 mg IV
TRV130 every 4 hours (q4h) against placebo IV
q4h and 4 mg morphine IV q4h. The second
phase tested 0.5 mg, 1 mg, 2 mg, or 3 mg every
3 hours (q3h) against placebo IV q4h and 4 mg
morphine IV q4h. In the first phase, 2 mg and
3 mg TRV130 showed better numeric rating
scale (NRS) scores of pain intensity reductions
over 48 hours (NRS TWA0-48) than placebo,
similar to morphine. In the second phase,
TRV130 3 mg was more statistically efficacious
than morphine 4 mg. No severe adverse events
occurred in either phase of the study for
TRV130, though some side effects were reported
(nausea, dizziness, headache, and vomiting).
TRV130 showed a smaller effect on oxygen
saturation than morphine did [35] (Table 1).
Oliceridine was shown to be an effective and
relatively safe IV analgesic for the treatment of
postoperative pain related to abdominoplasty in
a 2019 study. This was a phase 3, double-blind,
randomized placebo- and active-controlled
study evaluating the safety and efficacy of oliceridine in treating abdominoplasty-related
pain. The patients in the study received a
loading dose of oliceridine 1.5 mg, morphine
4 mg, or placebo IV, which was then followed
by demand doses of 0.1 mg, 0.35 mg, and
0.5 mg administered by either the patient or
clinician. Except for the placebo group, all
treatment groups showed a markedly decreased
need for rescue doses during the treatment
course. The placebo group showed the highest
occurrence of rescue pain medication use. Oliceridine-related severe adverse events were
limited to syncope and lethargy during the
study. The other extreme adverse events

observed during treatment were related to other
factors. Gastrointestinal adverse events showed
a proportional dose-related relationship with
oliceridine use up to 0.5 mg. The incidence of
gastrointestinal adverse events was similar to
that of the morphine group [36].

CONCLUSION
Pain is universal and serves a physiological
function in its most acute form. While most
forms of acute pain resolve with tissue healing,
it can also become chronic through the process
of pain chronification [1, 2, 5]. The treatment of
chronic pain has a remarkable history, altered
by drug availability, research, marketing, and
even the political climate. Without necessary
caution about their potential for abuse and side
effect profile, opioids entered the forefront of
the chronic pain market. Opioids in their natural, semisynthetic, and synthetic forms all
serve a similar purpose of analgesia and have
proven to be very effective in their realm of pain
relief [37–39]. The search for breakthrough pain
relief in patients with chronic pain conditions,
most commonly cancer-related, led to considerations of which medications to use and how
to administer them. Other concerns, including
the various side effect profile and addictive
potential of opioids, opened the conversation
for medications like oliceridine. As the prevalence of chronic pain increases, it is becoming
increasingly important to find safe and effective
medications to treat these conditions. Pain is
costly in the economic realm and takes a significant toll on patients’ quality of life. Thus, a
continued goal of medical research involves
exploring the effectiveness of opioids in terms
of analgesia while simultaneously reducing the
side effects and abuse potential.
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